Physician profile
Alan J Ruby
NPI 1801828025
$34,783.62
in general payments reported to CMS, 2019-2025
14 companies · $1,402 in 2025
The $1,402 reported for 2025 was more than what 84% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,534 · 2020: $6,947 · 2021: $16K · 2022: $1,893 · 2023: $1,290 · 2024: $2,349 · 2025: $1,402.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,854 · Consulting Fee: $2,187.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,854.31 |
| Consulting Fee | $2,187.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $18,408.48 | 2019-2025 | Eylea Hd, Eylea |
| Allergan, INC. | $12,118.70 | 2019-2021 | |
| Coherus Oncology, INC. | $1,375.00 | 2021 | |
| Genentech USA, INC. | $1,206.82 | 2020-2025 | Vabysmo |
| Alimera Sciences, INC. | $767.06 | 2022-2023 | Iluvien |
| Astellas Pharma US INC | $345.59 | 2023-2025 | Izervay |
| Abbvie INC. | $250.47 | 2022-2025 | Ozurdex |
| Biogen, INC. | $94.99 | 2022-2023 | |
| Asd Specialty Healthcare, LLC | $89.69 | 2022 | |
| Novartis Pharmaceuticals Corporation | $37.97 | 2019-2020 | |
| Apellis Pharmaceuticals, INC. | $33.62 | 2023 | Syfovre |
| Bausch & Lomb Americas INC. | $22.73 | 2022 | |
| Novo Nordisk INC | $18.95 | 2025 | Rybelsus, Ozempic |
| Ani Pharmaceuticals, INC. | $13.55 | 2025 | Iluvien |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alan Ruby listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.